Your browser doesn't support javascript.
loading
Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki, Yohei; Yoshihara, Yasuo; Nojima, Kiyoko; Momose, Haruka; Fukushi, Shuetsu; Moriyama, Saya; Wagatsuma, Ayumi; Numata, Narumi; Sasaki, Kyohei; Kuzuoka, Tomoyo; Yato, Yoshiyuki; Takahashi, Yoshimasa; Maeda, Ken; Suzuki, Tadaki; Mizukami, Takuo; Hamaguchi, Isao.
Afiliación
  • Seki Y; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Yoshihara Y; National Hospital Organization Murayama Medical Center, Tokyo 208-0011, Japan.
  • Nojima K; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Momose H; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Fukushi S; Department of Virology 1, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Moriyama S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Wagatsuma A; National Hospital Organization Murayama Medical Center, Tokyo 208-0011, Japan.
  • Numata N; National Hospital Organization Murayama Medical Center, Tokyo 208-0011, Japan.
  • Sasaki K; National Hospital Organization Murayama Medical Center, Tokyo 208-0011, Japan.
  • Kuzuoka T; National Hospital Organization Murayama Medical Center, Tokyo 208-0011, Japan.
  • Yato Y; National Hospital Organization Murayama Medical Center, Tokyo 208-0011, Japan.
  • Takahashi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Maeda K; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Mizukami T; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan. Electronic address: tmiz@nih.go.jp.
  • Hamaguchi I; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Med ; 3(6): 406-421.e4, 2022 06 10.
Article en En | MEDLINE | ID: mdl-35815933
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inmunización Secundaria / Inmunogenicidad Vacunal / COVID-19 / Vacuna BNT162 / Anticuerpos Antivirales Tipo de estudio: Prognostic_studies Idioma: En Revista: Med Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inmunización Secundaria / Inmunogenicidad Vacunal / COVID-19 / Vacuna BNT162 / Anticuerpos Antivirales Tipo de estudio: Prognostic_studies Idioma: En Revista: Med Año: 2022 Tipo del documento: Article